4-(Morpholine-4-carbonyl)phenylboronic acid
Product Information
Molecular Formula
C11H14BNO4
Molecular Weight
235.04
Description
4-(Morpholine-4-carbonyl)phenylboronic acid is a highly consequential compound deeply embedded in the biomedical sector and operates as an exceptionally versatile foundational unit for the creation of potential pharmacological interventions meticulously tailored to combat precise maladies. By reason of its potent boronic acid attributes intertwined with an intricate phenyl framework, this compound showcases an auspicious potentiality poised to revolutionize the realm of therapeutic approaches for a multitude of afflictions, encompassing the realms of oncology, endocrinology, and immunology.
Synonyms
(4-(Morpholine-4-carbonyl)phenyl)boronic acid; [4-(morpholine-4-carbonyl)phenyl]boronic Acid; 4-(Morpholinocarbonyl)phenyl boronic acid; 4-(Morpholine-4-carbonyl)phebylboronic acid; 4-(Morpholinocarbonyl)benzeneboronic Acid; 4-(Morpholin-4-ylcarbonyl)benzeneboronic acid; BORONIC ACID, [4-(4-MORPHOLINYLCARBONYL)PHENYL]-; 4-Morpholine-4-carbonylphenylboronic acid; (4-(Morpholine-4-carbonyl)phenyl)boronicacid; [4-(4-morpholinylcarbonyl)phenyl]boronic acid
IUPAC Name
[4-(morpholine-4-carbonyl)phenyl]boronic acid
SMILES
B(C1=CC=C(C=C1)C(=O)N2CCOCC2)(O)O
InChI
InChI=1S/C11H14BNO4/c14-11(13-5-7-17-8-6-13)9-1-3-10(4-2-9)12(15)16/h1-4,15-16H,5-8H2
InChI Key
KMNLIQJXZPBCDU-UHFFFAOYAF
Flash Point
Not applicable
Purity
98%
Computed Properties
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
2
Exact Mass
235.1015881 g/mol
Monoisotopic Mass
235.1015881 g/mol
Topological Polar Surface Area
70Ų
Heavy Atom Count
17
Formal Charge
0
Complexity
260
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| WO-2021007477-A1 | Indazoles and azaindazoles as lrrk2 inhibitors | 2019-07-11 |
| CA-3145305-A1 | Indazoles and azaindazoles as lrrk2 inhibitors | 2019-07-11 |
| WO-2020121261-A1 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| US-2020223827-A1 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| AU-2019398910-A1 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| CA-3120240-A1 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| CN-113330001-A | 3, 3-difluoroallylamine or salt thereof and pharmaceutical composition containing same | 2018-12-14 |
| EP-3894398-A1 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| KR-20210092312-A | 3,3-difluoroallylamine or salts thereof and pharmaceutical compositions comprising the same | 2018-12-14 |
| JP-2022512398-A | 3,3-Difluoroallylamine or a salt thereof and a pharmaceutical composition containing them. | 2018-12-14 |
